Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Depressive Disorder, Major

In brief

Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients

Key facts

Study ID
NCT06860958
Run by
Tanta University
People needed
60
Starts
2025-03-01
Expected to finish
2027-08-20
Last updated by the study team
2026-05-04

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.